Global Cancer Cachexia Market

Cancer Cachexia Market Size, Share, Growth Analysis, By Product(Progestogens, Corticosteroids), By Distribution Channels(Hospital Pharmacy, Retail Pharmacy), By Mechanism of Action(Appetite Stimulators and Weight Loss Stabilizers) - Industry Forecast 2024-2031

Report ID: SQMIG35A2857 | Region: Global | Published Date: March, 2024
Pages: 185 | Tables: 89 | Figures: 72

To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cancer Cachexia Market size was valued at USD 2.31 Billion in 2022 and is poised to grow from USD 2.42 Billion in 2023 to USD 3.47 Billion by 2031, growing at a CAGR of 4.6% in the forecast period (2024-2031)

The competitive environment of the Cancer Cachexia Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Established organizations within the industry leverage techniques inclusive of product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position. Additionally, the market is witnessing elevated opposition from local and neighborhood producers supplying cost-powerful options. 'Aeterna Zentaris', 'Aphios Corporation', 'Bristol-Myers Squibb Company', 'Pfizer Inc.', 'Helsinn Group', 'Merck KGaA', 'Artelo Biosciences Inc.', 'NGM Biopharmaceuticals', 'Aveo Oncology', 'Aavogen Inc.', 'Green Cross Wellbeing Corporation', 'Cannabics Pharmaceuticals Inc.', 'TCI Peptide Therapeutics', 'Fresenius Kabi', 'Tetra Bio-Pharma', 'Actimed Therapeutics'

Current treatment options for cachexia in cancer patients are limited to drugs such as progestogens, corticosteroids, and others. These drugs have shown efficacy in the treatment of cancer-induced cachexia, although there are clinical differences in treatment outcomes and no drug candidates are currently approved specifically for this condition. This increases the gap in therapeutic options, which market players are aiming to fill through R&D and the introduction of new drugs in the market.

In many cases, traditional approaches to treating patients with single-drug interventions provided limited therapeutic benefit. Also, due to the lack of approved drugs for this condition, healthcare providers have been seen turning to combination therapies to treat illness including both pharmacological and non-pharmacological. Clinical trials show significant improvement in body does not deny (LBM) in treated patients and combination therapies. Thus, such outcomes as the popularity of health professionals increase the acceptability of combination therapy among patient populations and drive the demand for cancer cachexia treatments in the market.

Related Reports

Cancer Pain Market
Buy Now GET FREE SAMPLE
Oncology Market
Buy Now GET FREE SAMPLE
Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Lung Cancer Market
Buy Now GET FREE SAMPLE
Breast Cancer Market
Buy Now GET FREE SAMPLE
Oncology Drugs Market
Buy Now GET FREE SAMPLE
Cancer Biomarkers Market
Buy Now GET FREE SAMPLE
Interventional Oncology Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Cancer Cachexia Market

Product ID: SQMIG35A2857

$5,300
BUY NOW